ReviewFrontiers in medicine2026
Stem cell therapies for biological repair in osteonecrosis: advances, challenges, and clinical insights.
Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteonecrosis is a bone condition that begins as an ischemic process and can progress to subchondral collapse and premature joint degeneration in untreated cases. Conventional treatments offer physical or symptomatic relief but do not address the underlying physiological deficiencies. Regenerative therapeutic techniques based on stem cells have been developed to stimulate osteogenesis, vascular therapeutic, and immunomodulation in bone defects. Existing clinical applications are based on mesenchymal stem cells (MSCs) derived from the bone marrow, peripheral blood, and adipose tissue, as well as engineered and pluripotent-derived constructs that are also in preclinical development. Preliminary clinical trials have indicated that stem cell therapy (SCT) can enhance symptoms and slow the progression of structural defects. However, inconsistent cell quality, non-standardized protocols, regulatory obstacles, and limited long-term outcomes are the key limitations. This review summarizes the available evidence, issues, and future trends in optimizing stem cell therapies for osteonecrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.